Statement of Principles concerning malignant neoplasm of the liver (Reasonable Hypothesis) (No. 31 of 2020)

The instrument uses a particular structure and terminology that governs how claim assessments are to be made.

• Reasonable hypothesis and application role. The Repatriation Medical Authority’s stated view is that there is “sound medical‑scientific evidence” that malignant neoplasm of the liver can be related to relevant service (s 8). The SoP then specifies objective factors which, if present and connected to relevant service, “must as a minimum exist” before a reasonable hypothesis is raised (s 9). The SoP therefore functions as an evidentiary threshold for administrative determinations under the VEA and MRCA (s 5).
• Condition definition and exclusions. The SoP defines “malignant neoplasm of the liver” as primary hepatocellular carcinoma and expressly excludes several other neoplasms and lymphomas (s 7(2)). The instrument notes the ICD‑10‑AM code but states the statutory definition controls (s 7(3)-(4)). That is important because coding alone (C22.0) is subordinate to the instrument’s textual definition.
• Factor catalogue. Section 9 lists 27 separate factors; any one suffices as the minimal factor to raise a reasonable hypothesis, subject to the factor being related to relevant service under s 10(1). Factors include chronic liver disease states (cirrhosis, steatohepatitis, autoimmune chronic active hepatitis), chronic viral infections (HBV, HCV, HDV, HIV), metabolic disease (diabetes mellitus, overweight/obesity), lifestyle exposures (alcohol consumption thresholds, smoking pack‑years, betel quid), drug/therapeutic exposures (immunosuppression for transplantation, combined oral contraceptives, anabolic‑androgenic steroids) and occupational/environmental exposures (ionising radiation cumulative dose, aflatoxin dietary exposure, vinyl chloride cumulative ppm‑years or hours, respirable asbestos fibres with differing thresholds for enclosed versus open environments, arsenic in drinking water). Several factors include precise quantitative thresholds and time windows before clinical onset (s 9; Schedule 1 for definitions).
• Temporal windows and latency. Many factors require exposures or disease to have existed a minimum number of years before “clinical onset” (commonly five years, sometimes ten or 30 years) and sometimes include maximum windows after cessation (eg combined oral contraceptives cessation within 30 years, anabolic steroids cessation within 20 years) (s 9).
• Cross‑references to technical standards. Certain factors require the use of external technical methodology or tests, for example laboratory confirmation of chronic hepatitis B, C or D (Schedule 1), calculation of cumulative equivalent ionising radiation dose using an ARPANSA guide (Schedule 1), and pack‑year calculations for tobacco with a specified conversion to mass of tobacco (Schedule 1).
• Interaction with other SoPs. Where a listed factor refers to an injury or disease for which another SoP exists, that other SoP applies to the extent of the reference (s 11).

These concepts anchor the SoP as a technical rulebook of defined exposures and thresholds that administrative decision‑makers will apply to veteran claims alleging service connection of hepatocellular carcinoma.

The instrument operates within the VEA/MRCA claims framework and therefore affects three classes of parties and several decision processes.

• Claimants. Primary affected persons are veterans and former members of the Forces whose claims for a condition, or for death attributable to a condition, fall under s 120A of the VEA or s 338 of the MRCA (s 5). The instrument explicitly intends to be used in relation to claims by “veterans, members of Peacekeeping Forces, or members of the Forces” under the VEA or MRCA (s 8). Claimants who have a diagnosis of malignant neoplasm of the liver, or whose dependants seek death benefits for death contributed to by the condition, are directly affected.
• Adversely affected parties by exclusion. Persons with cancers expressly excluded by the SoP (malignant neoplasm of the bile duct, carcinoid tumour, Hodgkin’s lymphoma, non‑Hodgkin lymphoma, soft tissue sarcoma) may not rely on this SoP, even if ICD coding could suggest inclusion; decision‑makers must apply the statutory definition, not the ICD code alone (s 7(2)-(4)).
• Decision‑makers and administrators. Administrators, medical officers, claims assessors and tribunals making determinations under the VEA and MRCA will use this SoP as the RMA’s specification of the factors that can raise a reasonable hypothesis of service connection. While the SoP does not itself determine entitlement, it materially affects the evidentiary assessment that underpins administrative decisions (ss 3, 5, 8-9).
• Medical experts and occupational hygienists. The SoP requires specific technical evidence for certain factors: laboratory confirmation for chronic viral infections (Schedule 1), cumulative equivalent radiation dose calculated in accordance with the ARPANSA guide (Schedule 1), pack‑year and alcohol consumption calculations (Schedule 1 and s 9 notes), and occupational exposure histories quantified in hours or ppm‑years (s 9; Schedule 1). This will draw in clinicians, radiological dosimetrists, occupational hygienists and forensic toxicologists to provide expert reports.
• Dependants and estates. The instrument expressly includes “death from malignant neoplasm of the liver” where death was from a terminal event or condition contributed to by the cancer (s 7(5); Schedule 1 definition of terminal event). Beneficiaries pursuing death or dependency claims are therefore affected, subject to the same factor and service‑connection rules.
• Employers and insurers indirectly. The SoP identifies occupational exposures (vinyl chloride, asbestos, arsenic in drinking water) with precise thresholds. While the SoP itself does not create employer liability, it will function within the veteran benefits system to determine service connection where the exposure occurred in service. That can affect liability and compensation narratives in other forums, and influence demands for records from employing authorities.

Who pays and who decides within the claims system is not set out in the SoP itself. The instrument is an RMA determination under the VEA (s 3). The SoP applies to claims “to which section 120A of the VEA or section 338 of the MRCA applies” (s 5). It therefore matters in the adjudication of benefits, including pension and compensation where the statutory decision‑maker treats the RMA’s SoP as the medical standard for raising a reasonable hypothesis.

The instrument sets out norms and rules for evidentiary assessment rather than prescriptive duties to third parties. The principal operative legal effects are these.

• Right to rely on listed factors to raise a reasonable hypothesis. A claimant has the right to rely on any one factor in section 9, if they can show the factor existed and that it is related to relevant service (ss 9, 10(1)). The SoP therefore identifies the medical and exposure scenarios that constitute a sufficient factual basis to advance the claim to the next stage of the administrative process.
• Duty to demonstrate the factor and its timing. Although the SoP does not allocate legal burdens in terms of “onus”, it requires factual showing because many factors demand objective evidence. For example, chronic infections with hepatitis B, C or D must be “confirmed by laboratory testing for hepatitis... serological or nucleic acid markers” and be of at least six months duration (Schedule 1). Radiation exposures must be calculated using the ARPANSA guide (Schedule 1). Tobacco exposure is framed as pack‑years with a specific conversion to grams of tobacco (Schedule 1). For alcohol the instrument prescribes measurement in kilograms of alcohol over a ten year period and specifies that the Australian Standard of ten grams per standard drink is used for calculation (s 9(9)-(10) note). These prescriptions create de facto duties on claimants to produce the specified types of evidence if they wish to rely on the factor.
• Temporal and relational requirement. The SoP requires that any factor shown must be related to the person’s relevant service (s 10(1)). For the special factor in s 9(27) (inability to obtain appropriate clinical management), the SoP narrows application to “material contribution to, or aggravation of” the cancer only where the cancer was suffered or contracted before or during relevant service (s 10(2)). These provisions constrains rights to rely on the factor catalogue to those where service connection can be shown.
• Cross‑application rights. Where a factor listed in s 9 refers to a disease or injury covered by another SoP, the other SoP governs the application of that factor “as in force from time to time” (s 11). That gives claimants the right to have relevant interrelated conditions assessed under the specialised SoP that addresses them, and imposes a duty on decision‑makers to apply the correct SoP.
• No penalties and no private rights of action created. The instrument contains no penal sanctions, regulatory prohibitions or private cause of action. It is an administrative medical statement to be used in claims assessment. Enforcement occurs through claims processes under the VEA and MRCA, not through criminal sanction (see ss 3, 5, 8-11).

Practically, the SoP converts epidemiological and clinical relationships into concrete, testable evidentiary elements that a claimant must produce and an assessor must consider. The Schedule’s definitions translate medical concepts into measurement rules, creating a regime where rights to progress a claim are contingent on producing defined forms of objective evidence calibrated to specified thresholds (Schedule 1; s 9).

The instrument does not create offences, fines or criminal penalties. It is an administrative statement of medical factors to be used by claim‑decision makers under the VEA and MRCA. The Repatriation Medical Authority’s power to make the statement is statutory, under subsection 196B(2) of the VEA (s 3). The SoP is therefore enforceable only in the sense that decision‑makers within the veteran claims framework must have regard to it when assessing whether a reasonable hypothesis has been raised by a claimant’s evidence.

Enforcement and consequences in practice are through administrative decisions:

• Adjudicative consequence. If a decision‑maker accepts that at least one of the s 9 factors existed in the claimant and that it was related to relevant service (s 10(1)), then, per the statutory scheme, a “reasonable hypothesis” of service connection will be said to have been raised. That has procedural consequences under the VEA/MRCA claims process because it requires the decision‑maker to proceed with further evidentiary consideration of causation and entitlement under the relevant statutes. The SoP operates as an evidentiary threshold, not as a penalty regime.
• No criminal or civil sanctions stated. The instrument does not prescribe sanctions for false statements, nor does it alter civil liability or tort law. The SoP does not itself create direct liability for employers, manufacturers or medical practitioners. It may, however, influence outcomes in other forums indirectly by establishing that certain exposures or conditions are recognised as capable of linking the disease to service.
• Administrative review and scrutiny. The SoP is a document that may be relied upon by claimants and used by decision‑makers; application of the SoP's rules can be reviewed through administrative appeals processes provided under the VEA and MRCA. The instrument itself contains no enforcement mechanisms but it will be part of the administrative record and a basis for internal or tribunal review of benefit decisions.

In short, the instrument functions as a binding medical reference within the administrative benefits framework, but does not contain enforcement mechanisms in the criminal sense. Its power is exercised within the adjudicative procedures set out by the VEA and MRCA, which are outside the text of this instrument; the SoP prescribes what must exist to raise a reasonable hypothesis, and administrative decision‑makers apply that standard when determining entitlement.

The instrument is expressly made under the VEA and applies to claims that fall under s 120A of the VEA or s 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) (s 3 and s 5). The interactions with other legal instruments and standards are explicit in several places.

• Statutory provenance. The SoP is made under subsection 196B(2) of the VEA (s 3). It therefore derives its legal operation from that statutory delegation. The instrument applies to claims within the VEA/MRCA claim structures, and decision‑makers under those Acts must apply it when assessing whether a reasonable hypothesis of service connection has been raised (s 5).
• Cross‑SoP application. Section 11 creates a direct interaction rule with other Statements of Principles: if a factor in s 9 refers to an injury or disease for which another SoP exists, that other SoP “applies in accordance with the terms of that Statement of Principles as in force from time to time.” This makes SoPs modular and potentially overlapping; decision‑makers must follow the specific SoP applicable to the referenced disease or injury (s 11).
• Technical standards and external guidance. The SoP incorporates or requires use of external technical materials: it refers to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD‑10‑AM) for coding (s 7(3)-(4)), and requires calculation of cumulative equivalent dose of ionising radiation in accordance with an ARPANSA guide dated and as in force on 2 August 2017 (Schedule 1 definition of cumulative equivalent dose). These external materials will guide how technical evidence is produced and assessed in claims. The instrument therefore interacts with administrative technical standards maintained by third parties.
• Medical testing standards. For chronic infection with hepatitis B, C or D, the SoP requires laboratory confirmation by serological or nucleic acid markers and a duration benchmark of at least six months (Schedule 1). That ties the SoP to clinical laboratory testing frameworks and to the evidentiary standards used in medical practice.
• Relationship to the diagnostic coding system. The SoP notes that while malignant neoplasm of the liver attracts ICD‑10‑AM code C22.0, the SoP’s definition is the operative meaning in applying the instrument (s 7(3)). Thus coding systems interact with, but are subordinate to, the instrument’s textual definitions.
• Interaction with claims statutes but not with other liability laws. The SoP is an administrative evidentiary tool within the VEA/MRCA regimes. It does not purport to displace or modify the content of other federal, state or territory statutes dealing with workplace safety, tort liability or insurance. It will, however, be a recognised statement of accepted medical and exposure relationships for veterans’ claims, and that factual recognition may influence other legal processes where the same evidence is relevant.

Overall, the SoP integrates statutory authority, technical external guides and cross‑SoP rules to create a framework for adjudicating service‑connection in liver cancer cases. Decision‑makers must apply the SoP alongside the governing provisions of the VEA and MRCA and with reference to the technical guides and laboratory standards referenced in the Schedule.

This instrument replaces one previous Repatriation Medical Authority Statement of Principles concerning malignant neoplasm of the liver (No. 21 of 2011). The instrument contains an express repeal provision: “The Statement of Principles concerning malignant neoplasm of the liver No. 21 of 2011 … is repealed” (s 4). The instrument itself is dated 24 April 2020 and commences on 25 May 2020 (ss 1-2).

No other amendments, transitional provisions, or staged commencements appear within the text of this instrument. The text also indicates that other Statements of Principles may change “as in force from time to time” and that where s 9 refers to a disease covered by another SoP, the other SoP applies in its terms as current (s 11). That mechanism allows future amendments to other SoPs to automatically affect how cross‑referenced factors are applied without further amendment to this instrument.

The Schedule incorporates external documents “as in force on 2 August 2017” for the ARPANSA guide on dose calculation (Schedule 1 definition of cumulative equivalent dose). That reference fixes a version of an external technical guide for the purposes of this SoP. Any later changes to that external guide will not, without further amendment of this SoP, be automatically incorporated; the SoP binds decision‑makers to the guide “as in force on 2 August 2017” for the purposes of cumulative equivalent dose calculation. This is an example of version‑locking an external technical standard within an SoP.

The instrument does not include a schedule of consequential amendments to other instruments, nor transitional provisions for claims lodged before the commencement date. The text contains no temporal savings for claims that may fall under the previous 2011 SoP. Practitioners should note that the 2011 SoP is expressly repealed (s 4) and that the 2020 SoP governs claims to which s 120A VEA or s 338 MRCA apply from its commencement date.

The instrument itself contains no citation of judicial decisions, and there is no litigation narrative included in the text. The SoP does not record any cases, appeals or tribunal decisions. It is a technical administrative instrument produced by the Repatriation Medical Authority; any litigation arising from its application would occur in the course of claims under the VEA or MRCA and in the administrative review and tribunal processes those Acts provide for, which are not detailed in this instrument.

Potential litigation or dispute conduits that practitioners should be mindful of, based on the instrument’s content, include the following areas of interpretive contest, because they involve factual quantification, technical methodology or service‑linking questions:

• Application and interpretation of temporal thresholds and cessation windows. Section 9 establishes multiple minimum exposure durations and minimum latency periods before “clinical onset”, and some factors require cessation windows (eg s 9(20), s 9(21), s 9(11)). Disputes may arise about the date of “clinical onset” and whether the timing requirements are satisfied by the evidence. The SoP defines “clinical onset” implicitly by reference to the time thresholds but does not elaborate how the date is to be ascertained in complex clinical courses. Such factual questions commonly form the subject of review.
• Use of technical guidance and dose reconstruction. For radiation dose (s 9(12) and Schedule 1), the SoP requires calculation “in accordance with” a specified ARPANSA guide. Litigated disputes in analogous contexts typically centre on the assumptions, models and data used in dose reconstruction. The SoP version‑locks the ARPANSA methodology “as in force on 2 August 2017” (Schedule 1). Challenges may arise about the correct application of that guide, the sufficiency of evidence for reconstruction, or the exclusion of background radiation as directed by the Schedule.
• Definitional vagueness and evidentiary phrases. Phrases such as “more days than not” for aflatoxin exposure or betel quid consumption (s 9(14), s 9(22)) and “inability to obtain appropriate clinical management” (s 9(27)) are fact‑sensitive and may generate disputes about evidentiary sufficiency and the legal meaning of the phrases. The instrument supplies a dictionary definition for some terms but not all,contentious terms will require factual determination.
• Occupational exposure quantification. Several occupational thresholds require cumulative hours or ppm‑years (s 9(15)-(18)). Disputes may focus on employment records, task descriptions, air monitoring data, and the correct conversion of monitoring results to ppm‑years or hours. The SoP’s precise numeric thresholds produce discrete yes/no factual questions that are amenable to litigation if evidence is contested.
• Cross‑SoP application. Section 11 requires application of other SoPs where a factor refers to another injury or disease. Disputes may arise about which SoP applies when conditions overlap or when one SoP has been updated since another. The SoP instructs that other SoPs apply “as in force from time to time” (s 11), which can generate litigation about the temporal application of amendments.

The instrument itself does not provide litigation history. Practitioners should therefore treat the SoP as a binding administrative standard within the VEA/MRCA adjudicative framework and expect interpretive and evidentiary disputes to be decided in the statutory review and tribunal processes applicable to veterans’ claims, using the SoP as the medical standard against which evidence is tested (ss 3, 5, 8-11).

The SoP contains a number of specific drafting choices, technical thresholds, definitional locks and temporal constraints that create practical pitfalls for claimants, advisers and decision‑makers.

• Definition overrides ICD coding. Although the instrument notes the usual ICD‑10‑AM code (C22.0) for hepatocellular carcinoma, it expressly states that the meaning of “malignant neoplasm of the liver” for the SoP is the text in s 7(2), which excludes cholangiocarcinoma (bile duct cancer) and certain neoplasms and lymphomas (s 7(2)-(4)). A claim supported only by an ICD code without clinical confirmation that the tumour is primary hepatocellular carcinoma may fail. Practitioners must check the clinical pathology and imaging records to ensure the tumour fits the statutory definition.
• Quantitative thresholds use non‑intuitive units. Alcohol is measured in kilograms of alcohol over ten year periods (s 9(9)-(10)), not standard drinks. The instrument supplies the calculation basis , ten grams per standard drink , but converting historical consumption to kilograms requires careful record‑taking and calculation. Smoking exposure uses pack‑years which the Schedule converts into grams of tobacco (1 pack‑year = 7.3 kg of tobacco), a conversion few lay records will directly state (Schedule 1).
• Technical evidence requirements. Chronic hepatitis B, C and D require laboratory confirmation of serological or nucleic acid markers and a duration of at least six months (Schedule 1). Radiation exposure requires dose reconstruction “in accordance with” a named ARPANSA guide “as in force on 2 August 2017” (Schedule 1). If claim evidence lacks these specific types of proof, decision‑makers may not accept these factors even if clinical suspicion exists.
• Different thresholds for similar exposures. Asbestos exposure thresholds differ sharply depending on whether exposure occurred in an enclosed space (1 000 cumulative hours, s 9(17)) or an open environment (3 000 cumulative hours, s 9(18)), and both require the exposures to have occurred while materials were being applied, removed, dislodged, cut or drilled and with first inhalation at least five years before clinical onset. Small variations in a work history can determine which threshold applies. Similarly, vinyl chloride has alternative criteria: 1 250 ppm‑years cumulative dose (s 9(15)) or 5 000 hours in specific production/processing roles (s 9(16)). Practitioners must map employment tasks precisely to these thresholds.
• Temporal windows for latency and cessation. Many factors require exposures to be at least five years before clinical onset (common across s 9 items), some require ten years, and some involve long cessation windows (eg combined oral contraceptive pill: continuous use for at least three years and clinical onset within 30 years of cessation, s 9(20)). Determining the date of “clinical onset” is therefore pivotal and can be contested.
• The “inability to obtain appropriate clinical management” factor is limited. Section 9(27) allows this factor but s 10(2) confines it to circumstances where the person’s malignant neoplasm of the liver was suffered or contracted before or during relevant service and then only to material contribution to, or aggravation of, the cancer. That means post‑service failures to obtain care will not operate under s 9(27) unless the cancer pre‑existed or was contracted before or during service. Practitioners must check timing carefully.
• “More days than not” and regional assumptions. Phrases like “on more days than not” for aflatoxin exposure or betel quid (s 9(14), s 9(22)) introduce probabilistic standards that require continuous or dominant exposure patterns and may be difficult to prove. The Schedule gives examples of geographical regions where high aflatoxin contamination is regular, but living or working in those regions must be proven by service records or deployment histories (Schedule 1).
• Cross‑SoP dependency complexity. Section 11 requires applying other SoPs where a factor refers to another injury or disease. Multiple overlapping SoPs can create complexity about which SoP controls and which thresholds to apply. The instruction that other SoPs apply “as in force from time to time” means that subsequent amendments in those SoPs will affect this instrument’s application without amendment here, which can create unpredictable changes in how a factor is judged.

These drafting features mean that evidence detail, precise temporal mapping, and technical expert reports are often required. Claimants and advisers who do not address the SoP’s specific numeric and definitional requirements risk failing to meet the SoP threshold even where a general causal story exists.

For practitioners advising claimants, compliance means assembling evidence that maps precisely onto the SoP’s factors, definitions and timing rules. The following is a practical checklist synthesised from the instrument’s requirements. Every item cites the relevant SoP provision or Schedule definition to show the legal basis for the evidence sought.

1. Confirm the clinical diagnosis and tumour type (s 7(2)-(4))

   • Obtain histopathology, imaging, and oncology reports that confirm a primary hepatocellular carcinoma arising from hepatocytes and exclude bile duct carcinoma, carcinoid tumour, Hodgkin’s lymphoma, non‑Hodgkin lymphoma and soft tissue sarcoma (s 7(2)).
   • Do not rely solely on ICD‑10‑AM code C22.0; use the clinical record to ensure the condition fits the instrument’s definition (s 7(3)-(4)).

2. Determine the date of clinical onset

   • For each factor, establish the claimant’s date of clinical onset of malignant neoplasm of the liver. Many factors require exposures or disease to have occurred a minimum number of years before clinical onset (s 9). If the onset date is unclear, obtain medical expert evidence to identify the most appropriate onset point for the purposes of the SoP thresholds.

3. Map exposures to the SoP factor list and thresholds (s 9)

   • Cirrhosis and chronic liver disease: obtain hepatology notes, fibrosis staging, imaging and biopsy reports showing cirrhosis before clinical onset (s 9(1), s 9(24), Schedule 1 definitions).
   • Chronic viral infections: secure laboratory reports confirming infection with hepatitis B, C or D with serological or nucleic acid markers and evidence of at least six months chronicity (s 9(2)-(4); Schedule 1).
   • HIV infection: confirm with serological testing and clinical records of timing (s 9(5)).
   • Diabetes mellitus: evidence of diagnosed diabetes with date of diagnosis and duration of at least five years before onset (s 9(7)).
   • Overweight/obese: compute BMI (W/H2) from documented height and weight, and show BMI ≥ 25 for at least five years within the 20 years before onset (s 9(8); Schedule 1).
   • Alcohol: produce a detailed alcohol history and convert to kilograms of alcohol using 10 grams per standard drink as the unit (s 9(9)-(10) note). For males show cumulative ≥ 110 kg in any ten year period at least five years before onset; for females ≥ 55 kg by the same rules.
   • Smoking: calculate pack‑years, ascertain start date and cessation date if applicable, and show smoking of at least ten pack‑years with smoking commencing at least five years before onset and, if ceased, onset within 20 years of cessation (s 9(11); Schedule 1).
   • Ionising radiation: commission dose reconstruction according to the ARPANSA guide referenced in the Schedule, and demonstrate a cumulative equivalent dose to the liver of at least 0.1 sievert at least five years before onset (s 9(12); Schedule 1).
   • Immunosuppression for transplantation: obtain transplant records and immunosuppressive therapy history with dates (s 9(13)).
   • Aflatoxin exposure: establish deployment or residence in geographical areas listed in the Schedule where aflatoxin contamination is regular and provide diet history showing such contaminated foods were a major part of the diet for “more days than not” for at least five years within the 30 years before onset (s 9(14); Schedule 1).
   • Vinyl chloride: reconstruct exposure in ppm‑years or document hours worked in production or processing (s 9(15)-(16)).
   • Asbestos: provide occupational history and, where available, monitoring or contemporaneous records to show cumulative hours in an enclosed environment (≥1 000 hours) or open environment (≥3 000 hours) while materials were being worked on, with first inhalation at least five years before onset (s 9(17)-(18)).
   • Physical activity: obtain clinical assessments or occupational records that evidence inability to undertake activity >3 METs for at least ten years within 15 years before onset (s 9(19); Schedule 1).
   • Contraceptives, steroids and betel quid: secure prescription, dispensing or clinical notes for combined oral contraceptive continuous use ≥3 years (with 30 year cessation window), anabolic‑androgenic steroid records showing cumulative 14 grams over ≥3 years and cessation timing, and history of betel quid/areca nut chewing on “more days than not” for ≥5 years with cessation windows as specified (s 9(20)-(22); Schedule 1).
   • Arsenic: document drinking water history or clinical evidence of chronic arsenic toxicity, showing average arsenic ≥50 µg/L for ≥10 years or equivalent cumulative exposure (s 9(23); Schedule 1).
   • Steatohepatitis, autoimmune chronic active hepatitis, specified metabolic or rare disorders: obtain specialist records documenting prior diagnoses and timing (s 9(24)-(26); Schedule 1 definitions).
   • Inability to obtain appropriate clinical management: collate contemporaneous evidence of lack of access to care, treatment refusals, or system denial, and ensure the cancer was suffered or contracted before or during service if relying on s 9(27) (s 10(2), s 9(27)).

4. Demonstrate relationship to relevant service (s 10)

   • For each factor relied upon, compile service records, deployment records, postings and contemporaneous logs that show the exposure was related to the person’s relevant service as defined in the Schedule (eg operational service, peacekeeping, hazardous service, British nuclear test defence service, warlike/non‑warlike MRCA service) (s 10(1); Schedule 1 definition of relevant service).
   • For exposures tied to geographic endemicity (eg aflatoxin), map service locations to the regions identified in the Schedule or to contemporaneous hazard reports.

5. Use appropriate experts and methodologies

   • For serological confirmations and chronicity of viral infections, rely on accredited laboratory reports and hepatitis specialists (Schedule 1).
   • For radiation dose reconstruction, commission an expert who uses the ARPANSA guide referenced in the Schedule and produce a documented methodology that follows the guide “as in force on 2 August 2017” (Schedule 1).
   • For occupational exposure quantification (asbestos, vinyl chloride, arsenic), seek occupational hygienist reports that translate job tasks and monitoring into the required cumulative hours or ppm‑years metrics.

6. Anticipate cross‑SoP application (s 11)

   • Identify if any factor refers to an injury/disease that has a separate SoP. If so, obtain and rely upon the other SoP’s terms as they are in force, since s 11 instructs decision‑makers to apply those SoPs where relevant.

7. Address definitional ambiguities

   • For phrases like “more days than not”, contemporaneous diaries, food records, witness statements and deployment ration logs can assist in proving frequent exposure.
   • For functional capacity (>3 METs), obtain exercise tests, cardiopulmonary exercise tests or disability assessments that quantify capacity in METs.

8. Assemble a clear chronology and conversion calculations

   • Provide conversion calculations for alcohol (grams → kilograms) and tobacco (pack‑years → grams) per the Schedule to avoid rejection for improper measurement.

9. Note limitations and alternative routes

   • If a factor cannot be established in the terms the SoP requires, assess whether another s 9 factor can be established. Any single factor suffices to raise a reasonable hypothesis so long as it is related to relevant service (s 9; s 10(1)).

10. Documentation and presentation for decision‑makers

    • Present a consolidated evidence bundle mapping each piece of evidence to the specific paragraph in s 9 and the Schedule definition it satisfies. Highlight dates relevant to the SoP’s latency and cessation windows and show service nexus information clearly.

Following this checklist aligns evidentiary preparation with the SoP’s precise technical demands. The SoP’s detailed thresholds and definitions create an evidentiary regime where careful conversion, technical expert reports and a clear service nexus are determinative of whether the SoP threshold for raising a reasonable hypothesis is met (ss 9-11; Schedule 1).